Midatech study approved in Poland

Midatech said it has received has oral confirmation from Polish regulators that the first in-human study of its sustained release product for treating carcinoid cancer has been approved.

Formal written confirmation of the approval is expected within the next two weeks, Midatech said.

At 9:40am: (LON:MTPH) Midatech Pharma Plc share price was +2p at 49.5p